169 related articles for article (PubMed ID: 37368037)
1. Assessment of antibody levels to SARS-CoV-2 in patients with idiopathic inflammatory myopathies receiving treatment with intravenous immunoglobulin.
Bae SS; Faure-Kumar E; Ferbas K; Wang J; Shahbazian A; Truong L; Yang H; McMahon M; FitzGerald JD; Charles-Schoeman C
Rheumatol Int; 2023 Sep; 43(9):1629-1636. PubMed ID: 37368037
[TBL] [Abstract][Full Text] [Related]
2. Antibody response after COVID-19 vaccination in intravenous immunoglobulin-treated immune neuropathies.
Svačina MKR; Meißner A; Schweitzer F; Ladwig A; Sprenger-Svačina A; Klein I; Wüstenberg H; Kohle F; Schneider C; Grether NB; Wunderlich G; Fink GR; Klein F; Di Cristanziano V; Lehmann HC
Eur J Neurol; 2022 Nov; 29(11):3380-3388. PubMed ID: 35842740
[TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin.
Volk A; Covini-Souris C; Kuehnel D; De Mey C; Römisch J; Schmidt T
BioDrugs; 2022 Jan; 36(1):41-53. PubMed ID: 34843105
[TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2 spike antibody concentration in gamma globulin products from high-prevalence COVID-19 countries are transmitted to X-linked agammaglobulinemia patients.
Raphael A; Shamriz O; Tvito A; Magen S; Goldberg S; Megged O; Lev A; Simon AJ; Tal Y; Somech R; Eisenberg R; Toker O
Front Immunol; 2023; 14():1156823. PubMed ID: 37063907
[TBL] [Abstract][Full Text] [Related]
5. Intravenous Immunoglobulin in Idiopathic Inflammatory Myopathies: a Practical Guide for Clinical Use.
Gandiga PC; Ghetie D; Anderson E; Aggrawal R
Curr Rheumatol Rep; 2023 Aug; 25(8):152-168. PubMed ID: 37261663
[TBL] [Abstract][Full Text] [Related]
6. Anti-SARS-CoV-2 Antibodies Within IVIg Preparations: Cross-Reactivities With Seasonal Coronaviruses, Natural Autoimmunity, and Therapeutic Implications.
Dalakas MC; Bitzogli K; Alexopoulos H
Front Immunol; 2021; 12():627285. PubMed ID: 33679770
[No Abstract] [Full Text] [Related]
7. Critical review of the role of intravenous immunoglobulins in idiopathic inflammatory myopathies.
Anh-Tu Hoa S; Hudson M
Semin Arthritis Rheum; 2017 Feb; 46(4):488-508. PubMed ID: 27908534
[TBL] [Abstract][Full Text] [Related]
8. IgG response to spike protein of SARS-CoV-2 in healthy individuals and potential of intravenous IgG as treatment for COVID-19.
Wang G; He Z; Wu F; Ge Z; Zhu J; Chen Z
Virol J; 2022 Nov; 19(1):186. PubMed ID: 36372879
[TBL] [Abstract][Full Text] [Related]
9. Intravenous immunoglobulin therapy for COVID-19 in immunocompromised patients: A retrospective cohort study.
Gröning R; Walde J; Ahlm C; Forsell MNE; Normark J; Rasmuson J
Int J Infect Dis; 2024 Jul; 144():107046. PubMed ID: 38615825
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal Observation of Immune Response for 23 Months in COVID-19 Convalescent Patients After Infection and Vaccination.
Xu J; Zheng J; Tan Y; Cai J; Xiang Y; Ling H; Li Z; Bai Q
Viral Immunol; 2023; 36(6):389-400. PubMed ID: 37276049
[TBL] [Abstract][Full Text] [Related]
11. Neutralizing and binding activities against SARS-CoV-1/2, MERS-CoV, and human coronaviruses 229E and OC43 by normal human intravenous immunoglobulin derived from healthy donors in Japan.
Kubota-Koketsu R; Terada Y; Yunoki M; Sasaki T; Nakayama EE; Kamitani W; Shioda T
Transfusion; 2021 Feb; 61(2):356-360. PubMed ID: 33104267
[TBL] [Abstract][Full Text] [Related]
12. Commercial Immunoglobulin Products Contain Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein.
Upasani V; Townsend K; Wu MY; Carr EJ; Hobbs A; Dowgier G; Ragno M; Herman LS; Sharma S; Shah D; Lee SFK; Chauhan N; Glanville JM; Neave L; Hanson S; Ravichandran S; Tynan A; O'Sullivan M; Moreira F; Workman S; Symes A; Burns SO; Tadros S; Hart JCL; Beale RCL; Gandhi S; Wall EC; McCoy L; Lowe DM
Clin Infect Dis; 2023 Oct; 77(7):950-960. PubMed ID: 37338118
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 spike protein antibody titers 6 months after SARS-CoV-2 mRNA vaccination among patients undergoing hemodialysis in Japan.
Kanai D; Wakui H; Haze T; Azushima K; Kinguchi S; Tsukamoto S; Kanaoka T; Urate S; Toya Y; Hirawa N; Kato H; Watanabe F; Hanaoka K; Hanaoka M; Mitsuhashi H; Yamaguchi S; Ohnishi T; Tamura K
Clin Exp Nephrol; 2022 Oct; 26(10):988-996. PubMed ID: 35751753
[TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 Antibody Longitudinal Profile of Immune Globulin Preparations.
Park HJ; Alcover KC; Wang Q; Gada SM
Mil Med; 2023 Jul; 188(7-8):1615-1619. PubMed ID: 35769049
[TBL] [Abstract][Full Text] [Related]
15. Are SARS-CoV-2 Antibodies Detectable in Human Milk After Vaccination Against COVID-19?
Scaggs Huang F
J Pediatric Infect Dis Soc; 2022 Apr; 11(4):126. PubMed ID: 35394545
[TBL] [Abstract][Full Text] [Related]
16. Effect of early treatment with polyvalent immunoglobulin on acute respiratory distress syndrome associated with SARS-CoV-2 infections (ICAR trial): study protocol for a randomized controlled trial.
Mazeraud A; Gonçalves B; Aegerter P; Mancusi L; Rieu C; Bozza F; Sylla K; Siami S; Sharshar T
Trials; 2021 Feb; 22(1):170. PubMed ID: 33648563
[TBL] [Abstract][Full Text] [Related]
17. Assessment of Broadly Reactive Responses in Patients With MERS-CoV Infection and SARS-CoV-2 Vaccination.
Zedan HT; Smatti MK; Thomas S; Nasrallah GK; Afifi NM; Hssain AA; Abu Raddad LJ; Coyle PV; Grivel JC; Almaslamani MA; Althani AA; Yassine HM
JAMA Netw Open; 2023 Jun; 6(6):e2319222. PubMed ID: 37389876
[TBL] [Abstract][Full Text] [Related]
18. Higher pro-inflammatory cytokines IL-6 and IFN-γ are associated with anti-SARS-CoV-2 spike protein-specific seroconversion in renal allograft recipients.
Yadav B; Prasad N; Kushwaha RS; Patel MR; Bhadauria D; Kaul A
Transpl Infect Dis; 2023 Oct; 25(5):e14133. PubMed ID: 37605477
[TBL] [Abstract][Full Text] [Related]
19. Antibody levels following vaccination against SARS-CoV-2: associations with post-vaccination infection and risk factors in two UK longitudinal studies.
Cheetham NJ; Kibble M; Wong A; Silverwood RJ; Knuppel A; Williams DM; Hamilton OKL; Lee PH; Bridger Staatz C; Di Gessa G; Zhu J; Katikireddi SV; Ploubidis GB; Thompson EJ; Bowyer RCE; Zhang X; Abbasian G; Garcia MP; Hart D; Seow J; Graham C; Kouphou N; Acors S; Malim MH; Mitchell RE; Northstone K; Major-Smith D; Matthews S; Breeze T; Crawford M; Molloy L; Kwong ASF; Doores K; Chaturvedi N; Duncan EL; Timpson NJ; Steves CJ
Elife; 2023 Jan; 12():. PubMed ID: 36692910
[TBL] [Abstract][Full Text] [Related]
20. Relapses of idiopathic inflammatory myopathies after vaccination against COVID-19: a real-life multicenter Italian study.
Conticini E; d'Alessandro M; Grazzini S; Fornaro M; Sabella D; Lopalco G; Giardina F; Colafrancesco S; Rizzo C; Guggino G; Priori R; Conti F; Iannone F; Bargagli E; Cantarini L; Frediani B
Intern Emerg Med; 2022 Oct; 17(7):1921-1928. PubMed ID: 35754076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
